Sunshine Biopharma Inc. filings document the reporting record of a public pharmaceutical company with Canadian generic-drug operations and proprietary oncology and antiviral development programs. Form 8-K disclosures cover operating results, material events, warrant solicitation arrangements, auditor changes, officer transitions and shareholder actions affecting common-stock matters.
Proxy and annual-meeting materials describe board elections, board committees, corporate governance, executive compensation, principal shareholders, related-party transactions, auditor ratification and equity incentive plan matters. The company’s filing record also includes late-filing notices for annual reports and capital-structure disclosures involving outstanding warrants and potential stock-split authority.
Sunshine Biopharma Inc. (SBFM) says Dr. Steve N. Slilaty, its Chief Executive Officer, approved the Series D Warrant provisions by written consent. Dr. Slilaty held 89.5% of the company’s voting power as of October 13, 2026. The approval becomes effective on the 20th day after the definitive information statement is mailed.
The provisions permit issuance of more than 20% of outstanding common shares at a deemed discount to Nasdaq Minimum Price, certain exercise-price and share-count adjustments after a share combination event, and voluntary exercise-price reductions by the board subject to Nasdaq rules. The exercise price and warrant share count will be adjusted for the October 26, 2026 reverse split after the approval takes effect; the adjustment has a $5.50 minimum exercise price and will not be repeated under that provision for this event. The October 9 offering generated approximately $6 million in gross proceeds before fees and expenses.
Sunshine Biopharma Inc. (SBFM) obtained written consent approving Series D warrant provisions. Chief Executive Officer Dr. Steve N. Slilaty approved them on October 13, 2026, when he held 89.5% of the company’s voting power. The approval takes effect on the 20th day after the definitive information statement is mailed.
The provisions cover issuance above 20% of outstanding common shares at a deemed discount, adjustments after a Share Combination Event, and voluntary exercise-price reductions, which are subject to Nasdaq rules. If a Share Combination Event occurs after approval becomes effective, the exercise price may be adjusted subject to a $0.275 floor, with the share count adjusted proportionately. Series D Warrants have a $0.66 initial exercise price and a five-year term commencing upon issuance. The October 9, 2026 offering included 10,509,082 Common Units and 400,000 Pre-Funded Units and generated approximately $6 million in gross proceeds before fees and expenses.
Sunshine Biopharma Inc. (SBFM) says CEO Dr. Steve N. Slilaty, who holds approximately 90% of the total voting power, approved three matters by written consent. The consent covers issuing more than 20% of outstanding common shares at a deemed discount to the Nasdaq Minimum Price immediately before execution of the Placement Agent Agreement for the public offering, which closed October 9, 2026.
The consent also approves adjustments to the exercise price or number of shares underlying Series D Warrants in a Share Combination Event, and voluntary exercise-price adjustments to outstanding Series D Warrants from time to time. It becomes effective 20 days after the definitive information statement relating to the consent is mailed to stockholders.
Sunshine Biopharma Inc. (SBFM) is the issuer in a Schedule 13G that lists BJI Financial Group with sole voting and sole dispositive power over 909,900 common shares, representing 6.0% of the class. Separately, Item 4 identifies Brian Walsh as the person filing and reports that he beneficially owns 0 shares (0%); the signature identifies Walsh as President.
Sunshine Biopharma Inc. (SBFM) common stock is the subject of a reported beneficial-ownership position of 1,588,266 shares by CVI Investments, Inc. and its investment manager, Heights Capital Management, Inc. The reported position equals 9.9% of the class and consists of 909,090 shares plus shares issuable upon warrant exercise. Both entities report shared voting and dispositive power over the same shares, with no sole voting or dispositive power.
The warrants cannot be exercised to the extent that doing so would cause beneficial ownership by a reporting person, its affiliates, and other persons whose ownership is aggregated with it under Section 13(d) to exceed 9.99%. The issuer's prospectus states that 15,219,383 shares were outstanding, excluding shares underlying the warrants, as of completion of the offering. Each reporting person disclaims beneficial ownership of the shares except for its pecuniary interest.
Sunshine Biopharma Inc. (SBFM) closed a best-efforts public offering of 10,909,082 units on October 9, 2026, generating approximately $6.0 million in gross proceeds before placement-agent fees and other expenses payable by the company. Common Units were priced at $0.55 and Pre-Funded Units at $0.54999; each included two Series D warrants, immediately exercisable at $0.66 per share and expiring five years from issuance. The Pre-Funded Warrants were exercised in full before closing.
Full cash exercise of the Series D warrants could provide approximately $14.4 million in additional gross proceeds, but exercise is not assured. The company expects to use net proceeds for general corporate purposes and working capital. Aegis Capital Corp. received 7% of the public offering price, a 1% non-accountable expense allowance, and reimbursement of certain accountable expenses. A Share Combination Event may trigger a price reduction if the lowest VWAP in the period spanning the five consecutive trading days immediately before and after the event is below the then-effective price; the new price is the greater of that VWAP and $0.275. The provision adjusts the share count to preserve aggregate exercise price, is limited to one adjustment, and is subject to any required stockholder approval.
Sunshine Biopharma Inc. (SBFM) is offering up to $6,000,000 in Common Units and Pre-Funded Units on a best-efforts basis. It offers up to 10,509,082 Common Units, each containing one common share and two Series D Warrants, and up to 400,000 Pre-Funded Units, each containing one Pre-Funded Warrant and two Series D Warrants; each Pre-Funded Unit sold reduces the Common Units offered one-for-one. There is no minimum offering amount required to close.
The assumed prices are $0.55 per Common Unit and $0.54999 per Pre-Funded Unit; actual pricing is negotiated. Series D Warrants have an initial $0.66 exercise price, are immediately exercisable and expire five years after issuance. Pre-Funded Warrants have a $0.00001 exercise price and no expiration date. Sunshine Biopharma estimates approximately $5.2 million in net proceeds for general corporate purposes, including working capital. Assuming a full Common Unit sale, no Pre-Funded Units and no warrant exercises, common shares outstanding would be 15,219,383, compared with 4,310,301 as of October 9, 2026. The warrants will not be listed, and the company does not expect a trading market to develop. Nasdaq requires a $1.00 minimum bid price, and the company says its shares recently traded below it.
Sunshine Biopharma Inc. (SBFM) is the issuer in Alta Partners LLC’s amended ownership report: Alta reported beneficial ownership of 200,000 common shares issuable upon exercise of outstanding warrants, equal to 4.905% of the class. Alta reported sole voting and dispositive power over 200,000 shares and no shared voting or dispositive power. Steven Cohen signed as Managing Member.
Sunshine Biopharma Inc. is registering a preliminary primary offering of up to $7,000,000, structured as up to 10,180,337 Common Units or substitute Pre-Funded Units on a one-for-one basis. Each Common Unit contains one common share and two Series D Warrants; each Pre-Funded Unit contains one Pre-Funded Warrant for a share plus two Series D Warrants. The registration also covers up to 10,180,337 shares underlying Pre-Funded Warrants and 40,721,348 shares underlying Series D Warrants. The assumed Common Unit price is $0.6876; the final price will be negotiated. Series D Warrants have an initial $0.6876-per-share exercise price and expire five years after issuance; Pre-Funded Warrants have a $0.00001-per-share exercise price.
The best-efforts offering has no minimum closing amount, so actual proceeds may be substantially less than the maximum. Sunshine estimates approximately $6.0 million in net proceeds after placement agent fees and estimated expenses, for general corporate purposes including working capital. Aegis Capital Corp. is the exclusive placement agent, and the offering is expected to end no later than November 30, 2026. Common shares outstanding were 4,310,301 as of October 1, 2026.